MeiraGTx Holdings (MGTX) EBIT (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly EBIT came in at $18.2 million in Q4 2025, up 157.92% YoY from $7.1 million in Q4 2024, and up 139.61% on a QoQ basis from -$46.1 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) EBIT (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of EBIT data on file, last reported at $18.2 million in Q4 2025.
- Quarterly EBIT rose 157.92% year-over-year to $18.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$106.6 million (up 35.87% YoY) and the FY2025 annual result came in at -$114.2 million, up 30.46% from the prior year.
- EBIT climbed to $18.2 million in Q4 2025, from -$46.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $18.2 million in Q4 2025 to a low of -$48.6 million in Q2 2024.
- A 5-year average of -$27.3 million and a median of -$30.1 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT plunged 439.33% — and 2025, when it soared 157.92%.
- Tracing MGTX's EBIT over 5 years: stood at -$7.7 million in 2021, then sank by 433.88% to -$41.1 million in 2022, then surged by 122.6% to $9.3 million in 2023, then sank by 439.33% to -$31.5 million in 2024, then soared by 157.92% to $18.2 million in 2025.
- The last three EBIT figures came in at $18.2 million (Q4 2025), -$46.1 million (Q3 2025), and -$38.8 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.12 Bn | 315.67 Mn | 244.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 244.43 Mn |
| Dec 31, 2025 | 18.24 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | -44.79 Mn |
| Mar 31, 2025 | -41.60 Mn |
| Dec 31, 2024 | -31.49 Mn |
| Sep 30, 2024 | -40.04 Mn |
| Jun 30, 2024 | -48.62 Mn |
| Mar 31, 2024 | -46.77 Mn |
| Dec 31, 2023 | -43.75 Mn |
| Sep 30, 2023 | -32.76 Mn |
| Jun 30, 2023 | -28.79 Mn |
| Mar 31, 2023 | -31.76 Mn |
| Dec 31, 2022 | -41.06 Mn |
| Sep 30, 2022 | -22.81 Mn |
| Jun 30, 2022 | -23.76 Mn |
| Mar 31, 2022 | -28.73 Mn |
| Dec 31, 2021 | -7.69 Mn |
| Sep 30, 2021 | -22.55 Mn |
| Jun 30, 2021 | -20.48 Mn |